Immunotherapy’s Dominance: Factors Driving the Market Share of Biologics in the US
The segment encompassing Immunotherapy and Biologic Therapy commands a considerable market share in the US Melanoma sector. This dominance is not just due to clinical efficacy but also the high pricing structure associated with these advanced, often proprietary, treatment regimes. As first-line treatments for advanced disease, these drugs represent the largest per-patient expenditure in the...
0 Comments
0 Shares
830 Views
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt